Sex Differences in Circulating Biomarkers of Cardiovascular Disease
- PMID: 31537263
- PMCID: PMC6756178
- DOI: 10.1016/j.jacc.2019.06.077
Sex Differences in Circulating Biomarkers of Cardiovascular Disease
Abstract
Background: Differences in proteomic profiles between men and women may provide insights into the biological pathways that contribute to known sex differences in cardiovascular disease (CVD).
Objectives: This study sought to investigate sex differences in circulating biomarkers representative of biological pathways implicated in the development of CVD among Framingham Heart Study participants.
Methods: The authors measured 71 circulating CVD protein biomarkers in 7,184 participants (54% women, mean age 49 years). Multivariable models were used to evaluate the associations of sex, menopause, and hormone status with biomarkers. Cox models were used to examine whether sex modified the association of biomarkers with incident CVD.
Results: Of 71 biomarkers examined, 61 (86%) differed significantly between men and women, of which 37 were higher in women (including adipokines and inflammatory markers such as leptin and C-reactive protein), and 24 were higher in men (including fibrosis and platelet markers such as MMP-8 (matrix metalloproteinase-8) and TIMP-1 (tissue inhibitor of metalloproteinases 1); false discovery rate q < 0.05 for all). Sex differences in biomarker profiles were most pronounced between pre-menopausal women versus men, with attenuated sex differences among post-menopausal women not taking hormone replacement therapy. Sex modified the association of specific biomarkers with incident CVD, including CD14 and apolipoprotein B (pinteraction <0.05 for all).
Conclusions: In a predominantly Caucasian population, the authors identified widespread sex differences in circulating biomarkers that reflect distinct pathways implicated in CVD, including inflammation, adiposity, fibrosis, and platelet homeostasis. Menopause and hormone status accounted for some, but not all, of the observed sex differences. Further investigation into factors underlying sex-based differences may provide mechanistic insight into CVD development.
Keywords: biomarkers; cardiovascular disease; female; sex.
Copyright © 2019 American College of Cardiology Foundation. All rights reserved.
Figures




Comment in
-
From Proteomics to Therapeutics: Sex Differences in Cardiovascular Disease Risk Do Matter.J Am Coll Cardiol. 2019 Sep 24;74(12):1554-1556. doi: 10.1016/j.jacc.2019.08.011. J Am Coll Cardiol. 2019. PMID: 31537264 No abstract available.
References
-
- Merz NC, Shaw LJ, Reis SE et al. Insights From the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study Part II: Gender Differences in Presentation, Diagnosis, and Outcome With Regard to Gender-Based Pathophysiology of Atherosclerosis and Macrovascular and Microvascular Coronary Disease. J Am Coll Cardiol 2006;47. - PubMed
-
- O’Meara E, Clayton T, McEntegart MB et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007;115:3111–20. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous